ArriVent BioPharma (NASDAQ:AVBP) Posts Earnings Results, Beats Expectations By $0.23 EPS

ArriVent BioPharma (NASDAQ:AVBP) posted its quarterly earnings data on Monday. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.23, FiscalAI reports. The company had revenue of $5.00 million during the quarter, compared to the consensus estimate of $0.80 million.

ArriVent BioPharma Trading Up 3.8%

NASDAQ AVBP traded up $0.52 on Monday, reaching $14.16. The stock had a trading volume of 905,956 shares, compared to its average volume of 746,557. The business has a 50 day moving average price of $23.05 and a 200 day moving average price of $26.66. ArriVent BioPharma has a 1 year low of $11.36 and a 1 year high of $35.83. The company has a market capitalization of $698.20 million, a price-to-earnings ratio of -3.91 and a beta of 1.66.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Oppenheimer restated an “outperform” rating and issued a $25.00 price objective on shares of ArriVent BioPharma in a report on Monday, October 26th. Truist Financial set a $21.00 target price on ArriVent BioPharma in a report on Monday, October 26th. B. Riley Financial dropped their price target on shares of ArriVent BioPharma from $45.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, October 20th. Wall Street Zen raised shares of ArriVent BioPharma from a “strong sell” rating to a “sell” rating in a report on Sunday, October 18th. Finally, Jefferies Financial Group set a $18.00 price objective on shares of ArriVent BioPharma in a research report on Tuesday, October 6th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, ArriVent BioPharma has an average rating of “Moderate Buy” and a consensus price target of $24.56.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision oncology therapies for patients with genetically defined cancers. The company’s primary focus is on targeted treatments for non-small cell lung cancer (NSCLC), particularly tumors driven by mutations in the epidermal growth factor receptor (EGFR) gene.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible EGFR tyrosine kinase inhibitor designed to target a range of EGFR mutations, including common mutations and exon 20 insertion mutations.